Computer-Aided Cell Analysis Enables Faster Diagnosis of Blood Diseases
|
By LabMedica International staff writers Posted on 11 Aug 2023 |

Blood disorders are frequently characterized by alterations in the quantities and shapes of red and white blood cells. Traditional methods for diagnosing the disease involves examining blood smears on a slide under a microscope, although evaluating these changes can be challenging even for experienced professionals, as subtle alterations can affect only a small fraction of the tens of thousands of visible cells. Consequently, distinguishing between diseases is not always simple. For instance, the visible changes in the blood of individuals with myelodysplastic syndrome (MDS), an early form of leukemia, often resemble those seen in less harmful types of anemia. The definitive diagnosis of MDS requires more invasive procedures such as bone marrow biopsies and molecular genetic testing.
Scientists from the German Cancer Research Center (DKFZ, Heidelberg, Germany) and the Cambridge Stem Cell Institute (Cambridge, UK) have now developed an artificial intelligence (AI) system capable of identifying and characterizing white and red blood cells in microscopic images of blood samples. This algorithm, named Haemorasis, aids physicians in diagnosing blood disorders and is publicly accessible as an open-source tool for research purposes. Initially, the scientists trained Haemorasis to recognize cell morphology using over half a million white blood cells and millions of red blood cells from more than 300 individuals with various blood disorders (including different forms of anemia and MDS).
Leveraging this acquired knowledge, Haemorasis can now propose diagnoses for blood disorders and even differentiate genetic subtypes of these conditions. Additionally, the algorithm uncovers significant associations between specific cell shapes and diseases, a task complicated by the sheer volume of cells involved. Haemorasis underwent testing on three distinct patient groups to confirm its efficacy across diverse test centers and blood count scanner systems. Tailored for hematology diagnostics, Haemorasis aids in providing a more accurate initial diagnosis of blood disorders, which is an essential step in identifying patients who may require more invasive procedures like bone marrow tests or genetic analysis. Ongoing studies will explore the potential limitations of the method.
"Automated cell analysis with Haemorasis could complement routine diagnosis of blood disorders in the future. So far, the algorithm has only been trained on specific diseases - but we still see great potential in this approach," said Moritz Gerstung of DKFZ.
Related Links:
German Cancer Research Center
Cambridge Stem Cell Institute
Latest Pathology News
- FDA Clears AI Digital Pathology Tool for Breast Cancer Risk Stratification
- New AI Tool Reveals Hidden Genetic Signals in Routine H&E Slides
- AI System Analyzes Routine Pathology Slides to Predict Cancer Outcomes
- New Tissue Mapping Approach Identifies High-Risk Form of Diabetic Kidney Disease
- Multimodal AI Tool Predicts Genetic Alterations to Guide Breast Cancer Treatment
- Interpretable AI Reveals Hidden Cellular Features from Microscopy Images
- Tumor Immune Structure Predicts Response to Immunotherapy in Melanoma
- Plug-and-Play AI Pathology System Classifies Multiple Cancers from Few Slides
- AI-Based Assays Support Risk Stratification in Prostate and Breast Cancer
- AI Pathology Model Predicts Immunotherapy Response in Lung Cancer
- Study Reveals Moleclar Mechanism Driving Aggressive Skin Cancer
- AI Precision Tests Deliver Cancer Risk Insights from Routine H&E Slides
- Collaboration Applies AI Pathology to Predict Response to Antibody-Drug Conjugates
- Biomarker Predicts Immunotherapy Response and Prognosis in Colorectal Cancer
- AI Improves Completeness of Complex Cancer Pathology Reports
- AI Tool Predicts Chemotherapy Response in Small Cell Lung Cancer
Channels
Clinical Chemistry
view channel
Noninvasive Urine Test May Support Earlier Diagnosis of Psychiatric Disorders
Delays in diagnosing serious psychiatric conditions can leave patients without timely support and complicate treatment planning. For bipolar disorder, average time to diagnosis can exceed nine years, and... Read moreAt-Home Blood and Cognitive Tests Support Dementia Risk Stratification
Dementia places a substantial burden on patients and health systems, and identifying individuals at elevated risk remains difficult at scale. In the UK, almost a million people are estimated to be living... Read moreMolecular Diagnostics
view channel
Emerging Biomarkers Advance Early Detection of MASLD and Liver Cancer Risk
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects about 30% of people worldwide and can advance to metabolic dysfunction-associated steatohepatitis (MASH), fibrosis, cirrhosis, and... Read more
Patented Isothermal Amplification Chemistry Advances Decentralized Testing
Molecular diagnostics offer high sensitivity for pathogen detection but typically rely on thermal cycling and specialized instruments, limiting their use outside centralized laboratories.... Read more
Finger-Prick Blood Test Aids Early Tuberculosis Detection and Risk Stratification
Household contacts of people with tuberculosis face an estimated 2% risk of developing disease, yet most are asymptomatic at the time of screening. Early-stage cases are often missed because symptom checks... Read more
Urine Test Beats MRI in Identifying Prostate Cancer Upgrading During Active Surveillance
Active surveillance is common for men with low-risk prostate cancer, yet deciding when to repeat biopsy remains challenging. Prostate-specific antigen (PSA) testing and magnetic resonance imaging (MRI)... Read moreHematology
view channel
Stem Cell Biomarkers May Guide Precision Treatment in Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is an aggressive blood cancer that most often affects older adults and still carries a poor prognosis despite therapeutic advances. Venetoclax-based regimens have improved... Read more
Advanced CBC-Derived Indices Integrated into Hematology Platforms
Diatron, a STRATEC brand, has introduced six advanced hematological indices on its Aquila, Aquarius 3, and Abacus 5 hematology analyzers. The new Research Use Only (RUO) indices include Neutrophil-to-Lymphocyte... Read moreImmunology
view channel
Biomarkers and Molecular Testing Advance Precision Allergy Care
Allergic diseases often present with similar symptoms but can be driven by distinct biological mechanisms, making standardized care inefficient for many patients. Historically, individuals with pollen... Read more
Point-of-Care Tests Could Expand Access to Mpox Diagnosis
Mpox outbreaks in non-endemic regions have underscored the need for rapid, accessible diagnostics to limit transmission. Polymerase chain reaction (PCR) remains the clinical reference, yet it depends on... Read moreMicrobiology
view channel
Molecular Urine and Stool Tests Do Not Improve Early TB Treatment in Hospitalized HIV Patients
Tuberculosis is the leading cause of death among people living with HIV, and diagnosis in hospital settings remains difficult. Symptoms are often non-specific, disease can be extrapulmonary, and many patients... Read more
Rapid Antigen Biosensor Detects Active Tuberculosis in One Hour
Tuberculosis remains a major global health challenge and continues to drive significant morbidity and mortality. The World Health Organization’s 2024 global report cites it as the leading cause of death... Read moreTechnology
view channel
Fully Automated Sample-to-Insight Workflow Advances Latent TB Testing
Latent tuberculosis remains a substantial testing workload for clinical laboratories as screening programs expand. Despite this growth, only about 40% of testing has shifted from traditional skin tests... Read more
Tumor-on-a-Chip Platform Models Pancreatic Cancer Treatment Response
Pancreatic cancer remains one of the hardest malignancies to treat because tumors are embedded within a dense microenvironment that shapes growth and therapy response. Standard laboratory models often... Read moreIndustry
view channel
Roche to Acquire PathAI for Up to $1.05 Billion to Strengthen AI Diagnostics Portfolio
Roche has entered into a definitive merger agreement to acquire PathAI, a company focused on digital pathology and artificial intelligence for pathology laboratories and the biopharma industry.... Read more




.jpg)



